Serum levels of cartilage oligomeric matrix protein. A predicting factor and a valuable parameter for disease management in rheumatoid arthritis.
- 1 May 2003
- journal article
- clinical trial
- Published by Taylor & Francis in Scandinavian Journal of Rheumatology
- Vol. 32 (3) , 156-161
- https://doi.org/10.1080/03009740310002498
Abstract
Objective: To examine whether cartilage oligomeric matrix protein (COMP) correlates with inflammation and/or joint destruction of patients with rheumatoid arthritis (RA) and to test COMP as predicting factor for the outcome of patients with established RA. Methods: Serum levels of COMP were measured in sera of 62 patients, suffering from RA according to the ACR criteria and treated in intervals in our department, over a period of 5 years. A commercially available sandwich – type ELISA‐kit developed by AnaMar Medical AB, Sweden, was used. The results of serum COMP were compared with the Disease Activity Score (DAS), the Larsen Score, and clinical and laboratory parameters. Results: We found a positive correlation between serum levels of COMP at baseline and deterioration of Larsen score even after 5 years (pConclusion: Serum levels of COMP is known to reflect increased cartilage turnover. The results indicate that serum COMP may be used as a prognostic marker of cartilage degradation in a patient group with established RA.Keywords
This publication has 19 references indexed in Scilit:
- Expression of cartilage oligomeric matrix protein (COMP) by embryonic and adult osteoblastsJournal of Orthopaedic Research, 2000
- Serum cartilage oligomeric matrix protein reflects osteoarthritis presence and severity: The Johnston county osteoarthritis projectArthritis & Rheumatism, 1999
- Analysis of cartilage oligomeric matrix protein (COMP) in synovial fibroblasts and synovial fluids.Rheumatology, 1998
- 5 What is the current status of biochemical markers in the diagnosis, prognosis and monitoring of osteoarthritis?Bailliere's Clinical Rheumatology, 1997
- Expression of cartilage oligomeric matrix protein by human synoviumFEBS Letters, 1997
- Increased degradation and alteered tissue distribution of cartilage oligomeric matrix protein in human rheumatoid and osteoarthritic cartilageJournal of Orthopaedic Research, 1996
- COMPARATIVE CONTROLLED TRIAL OF LOW-DOSE WEEKLY METHOTREXATE VERSUS AZATHIOPRINE IN RHUEMATIOD ARTHRITIS: 3-YEAR PROSPECTIVE STUDYRheumatology, 1990
- LONG-TERM OUTCOME OF TREATING RHEUMATOID ARTHRITIS: RESULTS AFTER 20 YEARSThe Lancet, 1987
- The development of disability in rheumatoid arthritisArthritis & Rheumatism, 1986
- Severe functional declines, work disability, and increased mortality in seventy‐five rheumatoid arthritis patients studied over nine yearsArthritis & Rheumatism, 1984